Kevin Larimore

647 total citations
16 papers, 452 citations indexed

About

Kevin Larimore is a scholar working on Clinical Biochemistry, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Kevin Larimore has authored 16 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Clinical Biochemistry, 7 papers in Genetics and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Kevin Larimore's work include Metabolism and Genetic Disorders (7 papers), Connective tissue disorders research (5 papers) and Muscle Physiology and Disorders (2 papers). Kevin Larimore is often cited by papers focused on Metabolism and Genetic Disorders (7 papers), Connective tissue disorders research (5 papers) and Muscle Physiology and Disorders (2 papers). Kevin Larimore collaborates with scholars based in United States, Australia and United Kingdom. Kevin Larimore's co-authors include Janet A. Thomas, Cary O. Harding, Soumi Gupta, Joy Olbertz, Haoling H. Weng, Roberto T. Zori, Jerry Vockley, Mingjin Li, Joy Jiang and Ravi Savarirayan and has published in prestigious journals such as New England Journal of Medicine, Scientific Reports and Journal of Immunological Methods.

In The Last Decade

Kevin Larimore

14 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Larimore United States 8 229 218 144 130 69 16 452
Jun Ye China 15 305 1.3× 312 1.4× 149 1.0× 127 1.0× 156 2.3× 50 590
Soledad Kleppe United States 8 160 0.7× 153 0.7× 82 0.6× 49 0.4× 32 0.5× 12 333
Lynn Hall United States 15 125 0.5× 437 2.0× 76 0.5× 52 0.4× 31 0.4× 22 741
Ubaldo Caruso Italy 15 338 1.5× 349 1.6× 48 0.3× 136 1.0× 150 2.2× 21 662
Yehani Wedatilake United Kingdom 10 187 0.8× 329 1.5× 59 0.4× 41 0.3× 68 1.0× 18 570
Yanling Yang China 17 373 1.6× 576 2.6× 61 0.4× 46 0.4× 125 1.8× 56 856
Andrew Y. Shuen Canada 11 75 0.3× 190 0.9× 138 1.0× 33 0.3× 24 0.3× 16 412
Aneal Khan Canada 13 131 0.6× 305 1.4× 73 0.5× 41 0.3× 18 0.3× 42 477
Teresa Kivisto United States 7 112 0.5× 205 0.9× 29 0.2× 156 1.2× 26 0.4× 8 376
Maciej Adamowicz Poland 11 44 0.2× 357 1.6× 108 0.8× 94 0.7× 52 0.8× 14 471

Countries citing papers authored by Kevin Larimore

Since Specialization
Citations

This map shows the geographic impact of Kevin Larimore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Larimore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Larimore more than expected).

Fields of papers citing papers by Kevin Larimore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Larimore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Larimore. The network helps show where Kevin Larimore may publish in the future.

Co-authorship network of co-authors of Kevin Larimore

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Larimore. A scholar is included among the top collaborators of Kevin Larimore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Larimore. Kevin Larimore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Henshaw, Joshua, Kevin Larimore, Jukka Puoliväli, et al.. (2025). BMN 351-Induced Exon Skipping and Dystrophin Expression in Skeletal and Cardiac Muscle Lead to Preservation of Motor Function in a Mouse Model of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics. 35(2). 81–92. 2 indexed citations
2.
Henshaw, Joshua, Kevin Larimore, Andrew C. Melton, et al.. (2025). Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Induces Enhanced Exon Skipping in a Mouse Model of Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics. 35(2). 68–80. 1 indexed citations
3.
Larimore, Kevin, Anu Cherukuri, Kala Jayaram, et al.. (2021). Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia. Clinical Pharmacokinetics. 61(2). 263–280. 20 indexed citations
4.
Prickett, Timothy C. R., Eric A. Espiner, Melita Irving, et al.. (2021). Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia. Scientific Reports. 11(1). 24278–24278. 2 indexed citations
5.
Zhou, Huiyu, Johanna R. Abend, Joy Olbertz, et al.. (2021). Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses. Molecular Genetics and Metabolism. 134(3). 235–242. 4 indexed citations
6.
Henshaw, Joshua, Soumi Gupta, Joy Olbertz, et al.. (2021). Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria. Clinical and Translational Science. 14(5). 1894–1905. 14 indexed citations
7.
Irving, Melita, Joel Charrow, Valérie Cormier‐Daire, et al.. (2021). Vosoritide for children with achondroplasia: a 60-month update from an ongoing phase 2 clinical trial. Molecular Genetics and Metabolism. 132. S101–S101. 4 indexed citations
8.
Burton, Barbara K., Nicola Longo, Jerry Vockley, et al.. (2020). Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Molecular Genetics and Metabolism. 130(4). 239–246. 19 indexed citations
9.
Larimore, Kevin, Roberto Zori, Gillian Shepherd, et al.. (2019). Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity. Journal of Immunological Methods. 468. 20–28. 7 indexed citations
10.
Savarirayan, Ravi, Melita Irving, Carlos A. Bacino, et al.. (2019). C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. New England Journal of Medicine. 381(1). 25–35. 135 indexed citations
11.
Irving, Melita, Joel Charrow, Valérie Cormier‐Daire, et al.. (2018). Vosoritide for Children with Achondroplasia: A 30 Month Update from an Ongoing Phase 2 Clinical Trial. Hormone Research in Paediatrics. 89.
12.
Zori, Roberto T., Janet A. Thomas, Natasha Shur, et al.. (2018). Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Molecular Genetics and Metabolism. 125(3). 217–227. 25 indexed citations
13.
Thomas, Janet A., Harvey L. Levy, Stephen Amato, et al.. (2018). Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Molecular Genetics and Metabolism. 124(1). 27–38. 134 indexed citations
14.
Gupta, Soumi, Cary O. Harding, Gillian Shepherd, et al.. (2018). Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 37. 366–373. 59 indexed citations
15.
Longo, Nicola, Roberto T. Zori, Melissa Wasserstein, et al.. (2018). Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. Orphanet Journal of Rare Diseases. 13(1). 108–108. 25 indexed citations
16.
Larimore, Kevin, et al.. (1988). A case report: cold hemagglutinin disease in a pancreatic and renal transplant patient. Immunohematology. 4(4). 71–74. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Ye Breakdown of academic impact, for papers by Soledad Kleppe Breakdown of academic impact, for papers by Lynn Hall Breakdown of academic impact, for papers by Ubaldo Caruso Breakdown of academic impact, for papers by Yehani Wedatilake Breakdown of academic impact, for papers by Yanling Yang Breakdown of academic impact, for papers by Andrew Y. Shuen Breakdown of academic impact, for papers by Aneal Khan Breakdown of academic impact, for papers by Teresa Kivisto Breakdown of academic impact, for papers by Maciej Adamowicz
Rankless by CCL
2026